Syneos Health Communications and Precision AQ led the agency list, while Novartis, Roche and Takeda shared the top client ...

GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...

Sanofi’s investigational BTK inhibitor tolebrutinib has demonstrated promising results in a phase 3 study of patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), which the ...

The pharmaceutical industry is committed to the development, manufacture and provision of medicines globally, a process that inevitably impacts the climate through greenhouse gases (GHG). To mitigate ...

Avalere Health has announced the appointment of Corrina Safeio as its new president, global marketing and executive vice president, corporate communications. In this role, Safeio will oversee the ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

Eli Lilly and artificial intelligence (AI)-focused Genetic Leap have entered into a research collaboration worth up to $409m to develop genetic medicines. The partnership will see the companies use ...

Johnson & Johnson (J&J) has shared positive longer-term data for its chemotherapy-free combination, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib), in adults with non-small cell lung cancer ...

Johnson & Johnson’s (J&J) dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative ...

The Medscape team will be returning to the Alliance Industry Summit in Philadelphia this year, bringing with them Best in Class Outcomes and support for the event. As part of their dedication to and ...